Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, will participate in the BofA Securities 2025 Health Care Conference. The company's CFO/COO Michael Kaseta and CMO Rajeev Saggar will deliver a business update in a fireside chat on May 13, 2025, at 1:40 PM PT / 4:40 PM ET in Las Vegas. Investors can access the webcast through Liquidia's website, where a recording will remain available for at least 30 days after the event.
Liquidia Corporation (NASDAQ: LQDA), un'azienda biofarmaceutica specializzata in trattamenti per malattie cardiopolmonari rare, parteciperà alla BofA Securities 2025 Health Care Conference. Il CFO/COO Michael Kaseta e il CMO Rajeev Saggar forniranno un aggiornamento aziendale durante un intervento informale il 13 maggio 2025 alle 13:40 PT / 16:40 ET a Las Vegas. Gli investitori potranno seguire la diretta streaming sul sito di Liquidia, dove la registrazione resterà disponibile per almeno 30 giorni dopo l'evento.
Liquidia Corporation (NASDAQ: LQDA), una empresa biofarmacéutica centrada en tratamientos para enfermedades cardiopulmonares raras, participará en la BofA Securities 2025 Health Care Conference. El CFO/COO Michael Kaseta y el CMO Rajeev Saggar ofrecerán una actualización empresarial en una charla informal el 13 de mayo de 2025 a la 1:40 PM PT / 4:40 PM ET en Las Vegas. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de Liquidia, donde la grabación estará disponible por al menos 30 días después del evento.
Liquidia Corporation (NASDAQ: LQDA)는 희귀 심폐 질환 치료에 중점을 둔 바이오제약 회사로, BofA Securities 2025 Health Care Conference에 참가합니다. 회사의 CFO/COO 마이클 카세타와 CMO 라지브 사가르는 2025년 5월 13일 오후 1시 40분 PT / 오후 4시 40분 ET 라스베이거스에서 진행되는 비공식 대화 형식의 사업 업데이트를 발표할 예정입니다. 투자자들은 Liquidia 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 녹화 영상은 행사 종료 후 최소 30일간 제공됩니다.
Liquidia Corporation (NASDAQ : LQDA), une entreprise biopharmaceutique spécialisée dans les traitements des maladies cardiopulmonaires rares, participera à la BofA Securities 2025 Health Care Conference. Le CFO/COO Michael Kaseta et le CMO Rajeev Saggar présenteront une mise à jour commerciale lors d'une discussion informelle le 13 mai 2025 à 13h40 PT / 16h40 ET à Las Vegas. Les investisseurs pourront accéder à la diffusion en direct via le site web de Liquidia, où l'enregistrement restera disponible pendant au moins 30 jours après l'événement.
Liquidia Corporation (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf seltene kardiopulmonale Erkrankungen spezialisiert hat, wird an der BofA Securities 2025 Health Care Conference teilnehmen. Der CFO/COO Michael Kaseta und der CMO Rajeev Saggar werden am 13. Mai 2025 um 13:40 Uhr PT / 16:40 Uhr ET in Las Vegas ein Business-Update in einem informellen Gespräch präsentieren. Investoren können den Webcast über die Website von Liquidia verfolgen, wo die Aufzeichnung mindestens 30 Tage nach der Veranstaltung verfügbar bleibt.
- None.
- None.
MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company’s Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada.
Access to a webcast will be available to investors and other interested parties by accessing Liquidia’s website at https://liquidia.com/investors/events-and-presentations.
An archived, recorded version of the presentation will be available on Liquidia’s website for at least 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When is Liquidia Corporation (LQDA) presenting at the BofA Securities Health Care Conference 2025?
Who will represent LQDA at the BofA Securities 2025 Healthcare Conference?
How can investors access Liquidia's presentation at the BofA Securities conference?
How long will the recording of LQDA's presentation be available?
